Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has filed U.S. and International patent applications for a novel combination product as a potential treatment of Netherton Syndrome. The product combines a serine protease inhibitor with an anti-inflammatory agent in a proprietary topical formulation. Quoin anticipates patents to extend to at least 2044, further strengthening their industry-leading position. They are currently enrolling patients in two clinical trials for the potential treatment of Netherton Syndrome with their QRX003 topical lotion.
Positive
The filing of U.S. and International patent applications for the novel combination product demonstrates Quoin's commitment to innovation and expanding their intellectual property portfolio.
Quoin is the only company actively recruiting subjects into Netherton Syndrome clinical trials being conducted under an open Investigational New Drug (IND) application.
Quoin Pharmaceuticals' patent applications for a novel combination product designed for Netherton Syndrome represent a strategic move to cement its position within a niche market. The focus on rare and orphan diseases allows Quoin to benefit from various incentives such as market exclusivity, tax credits and assistance with clinical trial costs, which are typically offered by regulatory agencies to encourage drug development in areas of unmet medical need.
From a market perspective, securing patents until at least 2044 could provide long-term revenue stability and deter competitors. The specific combination of a serine protease inhibitor with an anti-inflammatory agent in a topical formulation is noteworthy because it targets the underlying mechanisms of Netherton Syndrome, which is characterized by chronic skin inflammation and scaling. If successful, Quoin could potentially address a significant unmet medical need, as current treatment options are limited.
The clinical development of QRX003 and the filing of patent applications underscore Quoin's commitment to advancing treatment options for Netherton Syndrome. The therapeutic approach of combining a serine protease inhibitor with an anti-inflammatory agent could be a game-changer in managing the disease. Serine protease inhibitors can reduce the activity of enzymes that contribute to skin barrier dysfunction, while anti-inflammatory agents can mitigate the chronic inflammation associated with the syndrome.
Moreover, the fact that Quoin is the only company actively recruiting subjects for clinical trials under an open IND suggests a first-mover advantage in this therapeutic area. However, the success of this product will hinge on clinical trial outcomes, which will determine its efficacy and safety profile. Positive trial results could lead to a significant increase in Quoin's valuation due to the potential market monopoly in treating this rare condition.
Intellectual property is a critical asset for pharmaceutical companies, especially when it comes to novel treatments for rare diseases. Filing for both U.S. and International patents is a strategic move that protects Quoin's investment in research and development globally. The potential extension of these patents to at least 2044 is significant, as it would grant Quoin a prolonged period of market exclusivity, which is essential for recouping R&D investments and achieving profitability.
It is important to note that the strength of a patent portfolio can be a key factor in attracting investment and partnerships. Should these patent applications be granted, they could enhance Quoin's negotiating power in potential licensing deals or collaborations, which are common in the pharmaceutical industry for sharing the risks and rewards of drug development.
02/08/2024 - 08:00 AM
ASHBURN, Va., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company exclusively focused on the development and commercialization of innovative therapies that treat rare and orphan diseases, today announced it has filed U.S. and International patent applications for a novel combination product as a potential treatment of Netherton Syndrome.
This new product combines a broad spectrum serine protease inhibitor with an anti-inflammatory agent in a proprietary topical formulation. Quoin anticipates that patents arising from these applications will extend to at least 2044.
“As we continue to advance the clinical development of Quoin’s lead asset for Netherton Syndrome, we are pursuing opportunities to strengthen our industry-leading position in this disease space. Today’s announcement further underscores our commitment to innovation and to the expansion of our intellectual property portfolio. This novel product concept, formulated as a topical lotion, addresses the combined roles that serine protease inhibition and inflammation play in this disease,” said Dr. Michael Myers, Chief Executive Officer of Quoin.
Quoin is currently enrolling patients in two clinical trials being conducted under its open Investigational New Drug (IND) application, evaluating its QRX003 topical lotion as a potential treatment of Netherton Syndrome. To date, Quoin remains the only company actively recruiting subjects into NS clinical trials that are being conducted under an open IND.
To find our more about Quoin’s clinical studies, please visit http://www.nethertonsyndromeclinicaltrials.com/
About Netherton Syndrome
Netherton Syndrome, a form of Ichthyosis, is a rare, hereditary skin disorder caused by a mutation in the SPINK5 gene (serine protease inhibitor, Kazal Type 5) that leads to severe skin barrier defects and recurring infections, as well as a pronounced predisposition to allergies, asthma, and eczema. Patients also often suffer from severe dehydration, chronic skin inflammation and stunted growth.
About QRX003
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is an emerging specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises three products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa and others. For more information, go to: www.quoinpharma.com
Cautionary Note Regarding Forward Looking Statements
The Company cautions that statements in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as "expect," "intend," "plan," "anticipate," "believe," and "will," among others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the SEC on March 15, 2023, as updated by our subsequent filings with the SEC , and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.For further information, contact:
Quoin Pharmaceuticals Ltd.mmyers@quoinpharma.com
Investor Relationssprince@pcgadvisory.com
What is the latest development from Quoin Pharmaceuticals Ltd. (QNRX)?
Quoin Pharmaceuticals has filed U.S. and International patent applications for a novel combination product as a potential treatment of Netherton Syndrome.
What is the proprietary topical formulation developed by Quoin Pharmaceuticals Ltd. (QNRX)?
The proprietary topical formulation developed by Quoin Pharmaceuticals combines a broad spectrum serine protease inhibitor with an anti-inflammatory agent.
What clinical trials is Quoin Pharmaceuticals Ltd. (QNRX) currently conducting?
Quoin Pharmaceuticals is currently enrolling patients in two clinical trials under its open Investigational New Drug (IND) application, evaluating its QRX003 topical lotion as a potential treatment of Netherton Syndrome.
